Capadenoson in Angina Pectoris

• Status: Withdrawn
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• The primary diagnosis is chronic stable angina of mild-moderate intensity as defined by the Canadian Cardiovascular Society Functional Class II-III, in the presence of definitive coronary artery disease.

• Male or female subjects aged 35 to 75 years (if female, only if postmenopausal or permanently sterilized)

• Stable angina of mild-moderate intensity (Canadian class II-III) with anti-anginal medication not changed for the last 5 weeks

Exclusion Criteria:

• Inability to withdraw current anti-anginal therapy

• Inability to withdraw any concomitant therapy that would interfere with interpretation of study results